Tesamorelin
Tesamorelin is a synthetic growth hormone–releasing hormone analog used to stimulate endogenous growth hormone release. In the U.S., it is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general anti-aging, muscle-building, or routine weight-loss peptide.
Overview
Tesamorelin is marketed as EGRIFTA WR and acts on pituitary cells to increase growth hormone secretion, which can lower visceral abdominal fat in the approved HIV-lipodystrophy population. Reviews also discuss tesamorelin’s metabolic and liver-fat effects in people with HIV, but those uses are not the same as broad consumer wellness claims.
What it is
Tesamorelin is a peptide analog of growth hormone–releasing hormone (GHRH). It is a prescription drug, not a supplement, and it should be distinguished from non-approved “research peptide” products sold outside regulated channels.
Mechanism (high level)
Tesamorelin stimulates the pituitary gland to release endogenous growth hormone, which increases IGF-1 and can reduce visceral adipose tissue. The approved product labeling describes it as a GHRF analog, and the clinical effect most clearly established is reduction of excess abdominal fat in HIV-associated lipodystrophy.
Quick facts
- Dosage
- For EGRIFTA WR, the FDA-approved dosage is 1.28 mg subcutaneously once daily. The label also notes that EGRIFTA WR and EGRIFTA SV are not substitutable, and different formulations have different reconstitution and storage instructions.
- Route
- Subcutaneous injection (abdominal)
- Cycle
- No universal “cycle” is approved in the wellness sense. In practice, tesamorelin is used as an ongoing prescription therapy for the approved indication, and abdominal fat can re-accumulate after discontinuation. Clinical studies and reviews commonly assess outcomes over months rather than short cycles.
- Storage
- Follow the exact product instructions for the specific formulation dispensed EGRIFTA WR and EGRIFTA SV have different storage and preparation instructions Do not assume the two formulations are interchangeable Use only the manufacturer or pharmacy instructions provided with the prescription
Research indications
- HIV-associated lipodystrophy
- Excess abdominal fat in adults with HIV
- Visceral adipose tissue reduction research
- Metabolic dysfunction in HIV research
- NAFLD / liver-fat research in HIV
- Cardiometabolic risk-marker research in HIV
Research protocols (education)
Human protocols
1.28 mg subcutaneous once daily for current EGRIFTA WR labeling Older tesamorelin studies used earlier EGRIFTA formulations with different preparation instructions Clinical studies in HIV-associated lipodystrophy commonly evaluated outcomes over several months Liver-fat and metabolic studies in HIV have used controlled trial designs over extended follow-up
Interactions
Often avoided with
- Active malignancy
- Pregnancy
- Known hypersensitivity to tesamorelin or excipients
- Use for general weight-loss purposes
- Use outside prescription supervision
- Use with caution in people with glucose intolerance or diabetes
Often combined with
- Prescription use under clinician supervision
- Adults with HIV-associated lipodystrophy when prescribed
- Monitoring of IGF-1 and glucose when clinically indicated
- Structured follow-up for metabolic response and tolerability
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- Injection-site reactions
- Arthralgia
- Pain in extremity
- Peripheral edema
- Myalgia
- Pruritus
- Erythema
- Possible glucose intolerance
- Elevated IGF-1 concern
- Hypersensitivity reactions
Regulatory notes
- FDA approved prescription drug
- Approved only for reduction of excess abdominal fat in adults with HIV and lipodystrophy
- Not indicated for weight-loss management
- EGRIFTA WR and EGRIFTA SV are not substitutable
- Long-term cardiovascular safety has not been established
FAQ
What is tesamorelin?
Tesamorelin is a prescription GHRH analog peptide that increases endogenous growth hormone release and is approved in the U.S. for excess abdominal fat in adults with HIV-associated lipodystrophy.
Is tesamorelin FDA approved?
Yes. Tesamorelin is FDA approved as EGRIFTA WR for a specific indication: reducing excess abdominal fat in adults with HIV and lipodystrophy.
Is tesamorelin a weight-loss drug?
No. The label specifically says it is not indicated for weight-loss management.
How is tesamorelin taken?
The current EGRIFTA WR dosage is 1.28 mg subcutaneously once daily, using the exact preparation instructions for that specific formulation.
What is tesamorelin mainly used for?
Its main approved use is reducing visceral abdominal fat in adults with HIV-associated lipodystrophy
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.